Business Wire - Sepracor Inc. Announces Appointment of Lisa Ricciardi as Board Member
LYON, France — Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical market is available in its catalogue.
The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape
To order that report:
www.reportlinker.com/p063268/PRBW-Antibacterials-Market.html
For more information, contact Nicolas by email nbo@reportlinker.com , or by phone 33 4 37 65 17 03.
Introduction
Overview
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales.
Related Results
Popular prescription drugs
PFIZER.(Brief Article)(Statistical Data Included)
The Boston Globe business briefs column.
Pfizer: growth amid adversity
Local Focus.(Business)
The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.
Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance.
In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.
This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.
The following product classes are analyzed in this report: aminoglycosides, carbapenems, cephalosporins, dihydrofolate, reductase inhibitors, glycopeptides, ketolides, lipopeptides, macrolides, penicillins, oxazolidinones, pleuromutulins, quinolones.
The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription.
The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position.
The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.
The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.
Key Features of this report:
Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.
Table of content
1 EXECUTIVE SUMMARY
2 INTRODUCTION TO BACTERIAL DISEASES
2.1 Group A Streptococcus (GAS)
2.2 Group B Streptococcus (GBS)
2.3 Streptococcus pneumoniae
2.4 Haemophilus Influenzae
2.5 Neisseria Meningitidis
2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)
3 PATIENT DEMOGRAPHICS
3.1 Group A Streptococcus (GAS) Patient Statistics
3.2 Group B Streptococcus (GBS) Patient Statistics
3.3 Streptococcus pneumoniae Patient Statistics
3.4 Haemophilus Influenzae Patient Statistics
3.5 Neisseria Meningitidis Patient Statistics
3.6 MRSA Patient Statistics
4 KEY DRIVERS
4.1 Drug Resistance
4.2 New Treatments
4.3 PATIENT DEMOGRAPHICS
4.4 Vaccines
4.5 Potential for Clinical Success
4.6 Indirect Cost Associated with Infectious Diseases
5 KEY RESISTORS
5.1 Over-prescription
5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles
5.3 Acute Use of Antibiotics
5.4 Generics
5.5 Curative Therapies and Vaccines
6 THE MARKET
6.1 The Global Anti-infective Market
6.2 Market Segments
6.3 Global Antibacterial Market
6.3.1 Cephalosporin Antibiotics
6.3.2 Macrolide Antibiotics
6.3.3 Penicillin Antibiotics
6.3.4 Quinolone Antibiotics
6.3.5 Other Antibiotics
6.4 The Major Players
6.4.1 Antibacterial Major Players in 2006
6.4.2 Antibacterial Major Players in 2012
6.5 Market Trends
6.5.1 Antibacterial Agents by 2012
7 LEADING ANTIBACTERIAL DRUG CLASSES
7.1 Aminoglycosides
7.2 Carbapenems
7.3 Cephalosporins
7.4 Glycopeptide
7.5 Ketolide
7.6 Lipopeptide
7.7 Macrolides
7.8 Penicillins
7.9 Oxazolidinones
7.10 Pleuromutilins
7.11 Quinolone
8 LEADING BRANDS
8.1 Aminogylcoside Antibiotics
8.1.1 Tygacil (Wyeth)
8.1.2 Leading Aminoglycoside Sales Forecasts
8.2 Carbapenem Antibiotics
8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])
8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)
8.2.3 Primaxin/Tieman (Merck & Co.)
8.2.4 Leading Carbapenem Sales Forecasts
8.3 Cephalosporins
8.3.1 Ceftin/Zinnat (GlaxoSmithKline)
8.3.2 Flumarin (Shionogi)
8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)
